GTxBiopharma1 / 14Read in the app

Pitch deck

GTx's pitch deck

The deck, and the 3 rounds we watched GTx raise afterwards, with the investors each report named.

At GTx, They focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body.

14 slides2.2MBUSBiopharma

Read the deckFree account. The deck belongs to GTx, so reading it needs one; everything on this page is public.

What is in it

The deck, slide by slide

Each slide by what it argues. 14 slides against a median of 13 across the 1,712 decks we hold.

median
  1. 1Cover
  2. 2Market
  3. 3
  4. 4Market
  5. 5Competition
  6. 6Solution
  7. 7
  8. 8Market
  9. 9Market
  10. 10Vision
  11. 11Team
  12. 12Market
  13. 13Product
  14. 14Market

CoverMarketCompetitionSolutionVisionTeamProduct

  1. Nov 2014

    Venture$43M

    No investor was named in the report.

    Source recorded

  2. Mar 2014

    Round$21M

    No investor was named in the report.

    Source recorded

  3. Aug 2003

    Series E$20M

    Joseph R. Hyde IIIMB Venture Capital FundOracle Corporation

    Source recorded

Everyone who backed GTx

GTx pitch deck, cover slide1 / 14

The deck itself

Read GTx's full pitch deck

All 14 slides, each read for what it argues and set against the decks that raised at the same stage. The cover is shown here; the rest is read in the app.

Read the deck →Free account. The deck belongs to GTx.

More decks

Aurion BiotechBiopharma1 / 15SpaceXAI1 / 15$42B raised afterWeworkEnterprise1 / 36$12B raised afterUberTransportation1 / 25$11B raised after

Browse all 1,712 decks. We hold no record of where this file came from or on what terms. If it is yours and you would rather it were not here, tell us and it goes.